Results 41 to 50 of about 622 (105)

The effect of PLK1 inhibitor in osimertinib resistant non-small cell lung carcinoma cells. [PDF]

open access: yesZhejiang Da Xue Xue Bao Yi Xue Ban, 2023
Dai X   +6 more
europepmc   +1 more source

[Research on the clinical characteristics and prognosis of children with chronic myeloid leukemia in the blast phase]. [PDF]

open access: yesZhonghua Xue Ye Xue Za Zhi
Zheng FY   +6 more
europepmc   +1 more source

[Advances of Neoadjuvant Targeted Therapy in ALK-positive Non-small Cell Lung Cancer]. [PDF]

open access: yesZhongguo Fei Ai Za Zhi
Sun W, Zhou Y, Lin Y, Feng S, Long H.
europepmc   +1 more source

[Progress in molecular mechanisms and targeted therapies of persistent cancer cells]. [PDF]

open access: yesZhonghua Xue Ye Xue Za Zhi, 2023
Li X, Wang L, Zhao WL.
europepmc   +1 more source

[Application of high-throughput drug sensitivity testing in children with relapsed and refractory acute leukemia]. [PDF]

open access: yesZhongguo Dang Dai Er Ke Za Zhi
Qi WJ   +6 more
europepmc   +1 more source

[The guidelines for diagnosis and treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma in China (2025)]. [PDF]

open access: yesZhonghua Xue Ye Xue Za Zhi
Hematological Oncology Committee of China Anti-Cancer Association   +2 more
europepmc   +1 more source

[Research progress in systemic lupus erythematosus from 2021 to 2022]. [PDF]

open access: yesZhongguo Dang Dai Er Ke Za Zhi, 2023
Li YZ, Wu XC.
europepmc   +1 more source

Home - About - Disclaimer - Privacy